2026. Dexmedetomidine inhibits inflammation and angiogenesis and alleviates esophageal cancer progression through ITGA6/PI3K/AKT pathway: Dexmedetomidine inhibits esophageal cancer progression. Indian Journal of Experimental Biology (IJEB). 64, 01 (Feb. 2026), 15–32. DOI:https://doi.org/10.56042/ijeb.v64i01.22881.